Latest Trials

EudraCT Number: 2022-001796-14

Sponsor Protocol Number: CYTB323G12101

Start Date: 2023-03-20

Sponsor Name: Novartis Pharma AG

Full Title: An open-label, multi-center, phase 1/2 study to assess safety, efficacy and cellular kinetics of YTB323 in participants with severe, refractory systemic lupus erythematosus.

Medical condition: Systemic Lupus Erythematosus Lupus Nephritis

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	10028395 - Musculoskeletal and connective tissue disorders	10042945	Systemic lupus erythematosus	PT

Population Age: Adults

Gender: Male, Female

Trial protocol: DE (Ongoing) ES (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-004079-17

Sponsor Protocol Number: COMBATARF

Start Date: 2023-03-20

Sponsor Name: Rigshospitalet

Full Title: Efficacy and safety of 72-hour infusion of Prostacyclin (1 ng/kg/min) in mechanically ventilated patients with infectious pulmonary endotheliopathy – a multicentre randomized, placebo-controlled, b...

Medical condition: Infectious pulmonary endotheliopathy

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10038738 - Respiratory, thoracic and mediastinal disorders	10038696	Respiratory failure (excl neonatal)	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DK (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2022-002194-28

Sponsor Protocol Number: NL81713.078.22

Start Date: 2023-03-20

Sponsor Name: Erasmus MC

Full Title: Phase I/II study to determine the safety, immunogenicity and efficacy of Therapeutic Hepatitis B Virus Synthetic Long Peptide Vaccination (HEB-PEP-Study)

Medical condition: HBeAg negative chronic HBV

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.1	10021881 - Infections and infestations	10008910	Chronic hepatitis B	PT

Population Age: Adults

Gender: Male, Female

Trial protocol: NL (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-002966-34

Sponsor Protocol Number: TAK-861-2002

Start Date: 2023-03-20

Sponsor Name: Takeda Development Center Americas, Inc.

Full Title: A Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-861 for the Treatment of Narcolepsy Without Cataplexy (Narcolepsy Type 2)

Medical condition: Narcolepsy without Cataplexy (Type 2)

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10029205 - Nervous system disorders	10028713	Narcolepsy	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: NO (Completed) SE (Ongoing) FR (Ongoing) IT (Ongoing) ES (Ongoing) FI (Completed)

Trial results: (No results available)

EudraCT Number: 2022-001951-18

Sponsor Protocol Number: INS1009203

Start Date: 2023-03-17

Sponsor Name: Insmed Incorporated

Full Title: An Open-Label Extension Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term use of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Arterial Hypertension

Medical condition: Participants with Pulmonary Arterial Hypertension

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	10038738 - Respiratory, thoracic and mediastinal disorders	10064911	Pulmonary arterial hypertension	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Ongoing) ES (Ongoing) DK (Ongoing) IT (Ongoing) AT (Ongoing)

Trial results: (No results available)

EudraCT Number: 2021-005169-41

Sponsor Protocol Number: SL-372A

Start Date: 2023-03-16

Sponsor Name: ROXALL Medizin GmbH

Full Title: Phase II-III study to assess efficacy and safety of sublingual immunotherapy in patients suffering from house dust mite allergy

Medical condition: Patients with house dust mites related allergic rhinitis/rhinoconjunctivitis and well-controlled mild-to-moderate or without asthma

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.1	10038738 - Respiratory, thoracic and mediastinal disorders	10039085	Rhinitis allergic	PT
	20.0	10015919 - Eye disorders	10010744	Conjunctivitis allergic	PT
	21.1	10038738 - Respiratory, thoracic and mediastinal disorders	10001705	Allergic asthma	LLT

Population Age: Adults

Gender: Male, Female

Trial protocol: DE (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-003885-19

Sponsor Protocol Number: NOT-APPLICABLE-HUFA

Start Date: 2023-03-15

Sponsor Name:

Full Title: ECOGUIDED GENICULAR NERVE BLOCK IN PATIENTS WITH KNEE OSTEOARTHRITIS BY LOCAL ANESTHETIC OR BY COMBINATION OF LOCAL ANESTHETIC AND CORTICOID: PLACEBO-CONTROLLED RANDOMIZED BLIND CLINICAL TRIAL

Medical condition: KNEE OSTEOARTHRITIS

Disease:

Version

SOC Term

Classification Code

Term

Level

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-002593-89

Sponsor Protocol Number: TV48574-IMM-20038

Start Date: 2023-03-15

Sponsor Name: Teva Branded Pharmaceutical Products R&D, Inc.

Full Title: A 24-Week, Phase 2b, Randomized, Double-Blind Long-Term Extension Study to Evaluate Pharmacokinetics, Efficacy Safety, and Tolerability of TEV-48574 in Adult Patients with Moderate to Severe Ulcera...

Medical condition: Moderate to severe Ulcerative colitis or moderate to severe Crohn's disease

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.1	100000004856	10045365	Ulcerative colitis	LLT
	20.0	100000004856	10011400	Crohn's colitis	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Ongoing) CZ (Ongoing) SK (Ongoing) IT (Ongoing) BG (Ongoing) AT (Ongoing) HU (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-002540-42

Sponsor Protocol Number: XPORT-EC-042

Start Date: 2023-03-15

Sponsor Name: Karyopharm Therapeutics Inc.

Full Title: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE, ADVANCED OR RECURRENT ENDOMETR...

Medical condition: Selinexor/placebo will be given as maintenance therapy after combination chemotherapy for patients with p53 wild-type, advanced or recurrent endometrial cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10014733	Endometrial cancer	PT
	21.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10014734	Endometrial cancer metastatic	PT
	21.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10014736	Endometrial cancer recurrent	PT

Population Age: Adults

Gender: Female

Trial protocol: ES (Ongoing) DE (Ongoing) HU (Ongoing) BE (Ongoing) IE (Ongoing) IT (Ongoing) GR (Ongoing)

Trial results: (No results available)

EudraCT Number: 2022-003320-40

Sponsor Protocol Number: EP-003

Start Date: 2023-03-14

Sponsor Name: Empros Pharma AB

Full Title: A 26-week, double-blind, randomized study in participants with overweight or obesity investigating the added contribution of acarbose in EMP16 on efficacy, safety and tolerability

Medical condition: Obesity

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10027433 - Metabolism and nutrition disorders	10029883	Obesity	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: SE (Completed)

Trial results: (No results available)

Latest Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions